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Breaking and sealing one strand of DnA is an inherent feature of chromosome metabolism 
to overcome torsional barriers. Failure to reseal broken DnA strands results in protein-linked 
DnA breaks, causing neurodegeneration in humans. This is typified by defects in tyrosyl DnA 
phosphodiesterase 1 (TDP1), which removes stalled topoisomerase 1 peptides from DnA termini. 
Here we show that TDP1 is a substrate for modification by the small ubiquitin-like modifier 
sumo. We purify sumoylated TDP1 from mammalian cells and identify the sumoylation site 
as lysine 111. While sumoylation exhibits no impact on TDP1 catalytic activity, it promotes 
its accumulation at sites of DnA damage. A TDP1 sumoylation-deficient mutant displays 
a reduced rate of repair of chromosomal single-strand breaks arising from transcription-
associated topoisomerase 1 activity or oxidative stress. These data identify a role for sumo 
during single-strand break repair, and suggest a mechanism for protecting the nervous system 
from genotoxic stress. 
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Mutation of tyrosyl DNA phosphodiesterase 1 (TDP1) underlies the demise of postmitotic neurons observed in the human genetic neurological disease Spinocerebellar 
Ataxia with Axonal Neuropathy1. In budding yeast, TDP1 operates 
at DNA double-strand breaks (DSBs) primarily created by collision 
of replication forks with topoisomerase 1 (Top1) intermediates in 
proliferating cells2,3. In higher organisms, TDP1 additionally oper-
ates at single-strand breaks (SSBs), independently of DNA replica-
tion4–6. TDP1-deficient mammalian cells and postmitotic neurons 
display reduced rates of repairing SSBs arising from Top1 activity, 
hydrogen peroxide or ionizing radiation (IR)1,4,5,7,8. TDP1 also 
processes a variety of damaged 3′-termini such as 3′-phosphogly-
colate and 3′-abasic sites7,9–15. Although defects in TDP1 lead to 
accumulation of SSBs, cell-free studies suggest a requirement of 
high local concentrations of TDP1 to repair these structures16. 
However, it is not clear how this regulation is achieved in cells. Post-
translational modifications have been implicated in modulating 
the function of several DNA repair factors and channel repair to 
specific pathways. For example, phosphorylation of TDP1 by ATM 
or DNA-PK has been shown to promote its function at DSBs17,18. 
Phosphorylation by ATM during DSB repair has also been shown to 
promote the activity of polynucleotide kinase phosphatase19.
Here we identify TDP1 as a target for modification by the small 
ubiquitin-like modifier SUMO and provide evidence implicating 
SUMOylation in facilitating TDP1 cellular function during SSB 
repair.
Results
TDP1 is a substrate for modification by SUMO. Yeast two-hybrid 
analyses conducted to identify novel TDP1 binding partners 
uncovered 14 independent clones encoding full-length UBE2I, the 
human homologue of the yeast SUMO-conjugating enzyme UBC9 
(Fig. 1a). These observations suggested a previously unanticipated 
role for the SUMO modification pathway during TDP1-mediated 
repair. To test whether TDP1 is a substrate for covalent SUMO 
conjugation, we first reconstituted SUMOylation reactions in vitro 
using recombinant human p53, a known SUMO target20 (Fig. 1b). 
Parallel reactions conducted with human recombinant TDP1 
revealed a slower migrating band, as detected by anti-TDP1 or 
anti-SUMO1 antibodies (Fig. 1c). These products were absent from 
control reactions conducted in the presence of a SUMO1 mutant 
that is incapable of forming the covalent conjugation reaction. 
Furthermore, their appearance was dependent on ATP (Fig. 1d), 
confirming that they are covalent TDP1–SUMO1 conjugates. 
Subsequent comparison of the different SUMO isoforms suggested 
that TDP1 is preferentially modified by SUMO1 (Fig. 1e). As most 
SUMO target proteins are modified at very low steady-state levels 
in vivo, we ectopically expressed TDP1 and SUMO1 in mammalian 
cells and examined the possibility of covalent TDP1–SUMO1 
conjugations. For these experiments, we transfected HEK293 cells 
with Myc–TDP1 and/or green fluorescent protein (GFP)–SUMO1, 
followed by immunoprecipitation using anti-Myc antibodies. 
Probing the immunoprecipitate (IP) with anti-Myc antibodies 
revealed a discrete slower migrating band in Myc–IPs from extracts 
coexpressing Myc–TDP1 and GFP–SUMO1 (Fig. 1f). Importantly, 
this band was absent in Myc–IPs conducted on extracts expressing 
either Myc–TDP1 or GFP–SUMO1 alone. Furthermore, probing with 
anti-SUMO1 antibodies revealed a faint band in the input of extracts 
coexpressing Myc–TDP1 and GFP–SUMO1, but not in extracts 
expressing either Myc–TDP1 or GFP–SUMO1 alone. Enrichment 
of this band was observed following Myc–IPs, confirming that it is a 
TDP1–SUMO1 modification. Parallel experiments conducted using 
SUMO1, SUMO2 or SUMO3 isoforms were in agreement with the 
in vitro observations, suggesting that while TDP1 can be modified 
by all three SUMO isoforms its primary substrate appears to be 
SUMO1 (Fig. 1g).
Next, we tested whether endogenous TDP1 is covalently conju-
gated by SUMO1. For these experiments, we used HeLa cells stably 
expressing hexahistidine (6×His)-tagged SUMO1. We purified histi-
dine-tagged SUMO conjugates using nickel-charged beads and sub-
jected the conjugation products to immunoblotting using anti-TDP1 
antibodies. Endogenous TDP1–SUMO1 was enriched on nickel beads 
incubated with extracts expressing histidine-tagged SUMO1, but not 
with control HeLa cell extracts (Fig. 1h). That the enriched products 
correspond to TDP1–SUMO1 conjugates was confirmed by demon-
strating TDP1 activity that releases tyrosine from a 3′-phosphotyrosine 
synthetic Top1 substrate, which mimics Top1-linked DNA breaks 
(Fig. 1i). To further confirm that TDP1 is covalently SUMOylated in 
mammalian cells, we examined the effect of sentrin/SUMO-specific 
protease-1 (SENP1) on human purified SUMO1–TDP1 conjugates. 
SUMOylation is a dynamic process and once attached the SUMO 
peptide can be removed from target proteins by SENPs. For these 
experiments, we transfected HEK293 cells with His–GFP–SUMO1 
and/or Myc–TDP1 and purified histidine-tagged GFP–SUMO1 
conjugate using nickel-charged beads. Conjugation products were 
then subjected to Myc–IPs to purify Myc–TDP1–SUMO1–His–GFP 
products (Fig. 1j). Anti-Myc immunoblotting revealed a discrete 
band in Myc–IPs from extracts coexpressing Myc–TDP1 and His–
GFP–SUMO1 (Fig. 1k). Subsequent treatment of the Myc–IP with 
SENP1 resulted in a band corresponding in size to Myc–TDP1 
(Fig. 1l). Taken together, we conclude that TDP1 is covalently modi-
fied by SUMO1 in mammalian cells.
TDP1 is SUMOylated at lysine 111. To study the consequences of 
TDP1 SUMOylation, we aimed at identifying SUMOylation site(s). 
Most SUMO target proteins contain a specific stretch of ψKxE, 
where ψ is a large hydrophobic residue and K is the target lysine. 
In silico analyses revealed two potential SUMOylation sites in the 
N-terminal domain and three sites in the C-terminal domain (Fig. 2a). 
We mutated the predicted acceptor lysines to arginine and subjected 
the purified proteins to in vitro SUMOylation reactions. Notably, 
the N-terminal domain is only conserved in higher eukaryotes 
(Fig. 2b, dotted boxes) and database analyses revealed K111 to be con-
served across vertebrates. Consistent with SUMOylation occurring 
in this domain, reactions conducted in the presence of TDP11 − 150 
revealed a prominent slower migrating band (Fig. 2c, lane 1). This 
band was absent from reactions containing TDP11 − 150; K111R  
and instead a faster migrating band appeared with lower inten-
sity, suggesting a secondary SUMOylation site that was picked up 
in the absence of K111 in vitro (Fig. 2c, lane 2). Mutation of K139 
to arginine resulted in SUMOylated species with identical size to 
SUMOylated TDP11 − 150, albeit with higher intensity, suggest-
ing that K111 is the main SUMOylation site and that K139 may 
contribute to SUMOylation of the truncated TDP11 − 150 in vitro 
(Fig. 2c, lane 3). Indeed, mutation of both K111 and K139 to arginine 
completely abrogated SUMOylation of TDP11 − 150 (Fig. 2c, lane 4). 
The slower migrating band was SUMOylated TDP1, as it was absent 
in reactions containing a mutant form of SUMO that cannot be 
covalently conjugated (Fig. 2c, lanes 5 and 6). We next compared 
full-length recombinant TDP1 and TDP1K111R for their ability 
to covalently conjugate SUMO1 in vitro. Mutation of lysine 111 to 
arginine was sufficient to abolish SUMO1 covalent attachment 
to full-length TDP1 (Fig. 2d). We next examined whether lysine 
111 is the main SUMOylation site in vivo. For these experiments, 
we generated Myc–TDP1 and mutants in which the N-terminal, 
C-terminal or all predicted SUMO sites were mutated to arginine 
(Fig. 2e). We co-transfected HEK293 cells with the different forms 
of Myc–TDP1 and/or GFP–SUMO1, followed by immunoprecipita-
tion using anti-Myc antibodies. A single amino-acid substitution of 
K111 to arginine was sufficient to abrogate the formation of TDP1–
SUMO1 conjugates (Fig. 2e). Taken together, we conclude that K111 
is the main SUMOylation site in TDP1.
ARTICLE 

nATuRE CommunICATIons | DoI: 10.1038/ncomms1739
nATuRE CommunICATIons | 3:733 | DoI: 10.1038/ncomms1739 | www.nature.com/naturecommunications
© 2012 Macmillan Publishers Limited. All rights reserved.
SUMOylation-deficient mutant shows reduced rate of SSB repair. 
To examine the consequences of TDP1 SUMOylation in vivo, 
we compared the ability of HEK293 cells ectopically expressing 
SUMO1 and TDP1 or TDP1K111R for their ability to repair camp-
tothecin (CPT)-induced DNA damage using alkaline comet assays. 
These assays primarily measure repair of DNA SSBs, where they 
form and disappear with kinetics established for this repair proc-
ess4,5,21. As expected, HEK293 cells expressing TDP1 accumulated 
four- to fivefold fewer SSBs compared with control cells (Fig. 3a). 
Notably, cells expressing TDP1K111R accumulated two- to three-
fold more SSBs compared with TDP1-expressing cells (P = 0.0169; 
t-test). This defect was not due to differences in expression levels as 
confirmed by immunoblotting (Fig. 3b) and was evident from scat-
ter plots of the raw data from individual experiments (Fig. 3c). The 
difference in breaks is notable in terms of SSB repair, as ~4-fold dif-
ference underlies the severe neurological demise observed in neural 
tissues lacking XRCC1, the core SSB repair protein22. To examine 
whether the difference in repair was due to SUMOylation, we com-
pared CPT-induced SSBs in the presence and absence of ectopically 
expressed SUMO1. While overexpression of SUMO1 had no impact 
on CPT-induced SSBs in control cells and in TDP1K111R-expressing 
cells (Fig. 3d,e; P = 0.65; t-test), it reduced the extent of SSBs in 
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Figure 1 | Human TDP1 is SUMOylated in vitro and in mammalian cells. (a) Yeast Y190 cells containing the indicated constructs were examined for  
the activation of His3 and β-Gal reporter genes. (b) Recombinant p53 (430 nm) was incubated with 50 nm sAE1/sAE2, 500 nm uBC9, 5 mm ATP  
and 30 µm sumo1 ‘WT’ or mutant sumo1 that cannot be covalently conjugated ‘mT’. Reactions were fractionated by sDs–PAGE and analysed  
by anti-p53 immunoblotting (Activemotif). (c) Human full-length TDP1 (500 nm) was subjected to in vitro sumoylation reactions and analysed  
by anti-TDP1 (ab4166; Abcam) or anti-sumo1 (santa Cruz, sC-5308) immunoblotting. (d) sumoylation reactions were conducted in the presence 
or absence of 5 mm ATP. (e) sumoylation reactions conducted in the presence of sumo1, sumo2 or sumo3 were divided into three fractions and 
analysed by immunoblotting. (f) Total cell extract from HEK293 (~4×106 cells) transfected with myc–TDP1 and/or GFP–sumo1 was subjected to 
immunoprecipitation using anti-myc monoclonal antibodies (9B11; Cell signaling). Immunoprecipitates were analysed by immunoblotting using anti-myc 
(9B11) or anti-sumo1 (sC-5308) antibodies. Input is ~5% of total cell extract. (g) HEK293 cells transfected with myc–TDP1, HA-tagged His–sumo1,  
His–sumo2 or His–sumo3 were analysed by anti-TDP1 (ab4166) or anti-His (H1029) immunoblotting. (h) Lysates from control HeLa cells ‘C’ or cells 
stably expressing His–sumo1 ‘s1’ were mixed with ni2 +  charged agarose beads and histidine-tagged sumo conjugates ‘bound’ were analysed by  
anti-TDP1 immunoblotting. Input is ~3% of total cell extract. (i) Total cell extract ‘In’ (~20 µg) or ni2 +  beads enriched with histidine-tagged sumo 
conjugates ‘bound’ were mixed with 32P-radiolabelled 18-mer duplex (50 nm) harbouring a 3′-phosphotyrosine terminus ‘PY’, inset. Repair products were 
analysed by denaturing PAGE and phosphorimaging. Positions of the 32P-radiolabelled substrate ‘PY’ and product ‘P’ are indicated. (j) Diagram depicting 
purification of sumoylated TDP1 from mammalian cells. (k) serial dilutions of purified myc–TDP1 or myc–TDP1–sumo1–His–GFP were analysed by 
sDs–PAGE and anti-myc immunoblotting. (l) Purified myc-TDP1–sumo1–His–GFP was mock-treated ‘ − ’ or incubated with 250 ng of human sentrin/
sumo-specific protease-1 (sEnP1) ‘ + ’ and reaction products analysed by anti-myc immunoblotting. molecular weight size markers (kDa) are depicted. 
IB, immunoblot; IgG, immunoglobulin G; mT, mutant; WT, wild type.
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TDP1-expressing cells (P = 0.007; t-test). These observations suggest 
that the difference in repair observed between TDP1K111R and TDP1 
was due to SUMOylation of the latter. As TDP1 also repairs oxida-
tive SSBs resulting from IR23, we compared TDP1- and TDP1K111R-
expressing cells for their ability to repair IR-induced SSBs. While 
IR induced similar levels of SSBs in all three cell lines (Fig. 3f), the 
kinetics of their removal was delayed in cells expressing TDP1K111R 
compared with TDP1-expressing cells (Fig. 3g), suggesting a role for 
TDP1 lysine 111 during the repair of IR-induced SSBs.
To further examine the consequences of TDP1 SUMOylation in 
cells lacking endogenous TDP1, we infected Tdp1 − / −  mouse embry-
onic fibroblasts (MEFs) with retrovirus particles containing vector 
alone (Tdp1 − / −  V) or encoding human TDP1 (Tdp1 − / −  hTDP1) 
or TDP1K111R (Tdp1 − / −  hTDP1 − K111R). During 30-min incubation 
with CPT, Tdp1 − / −  V accumulated approximately fivefold more SSBs 
compared with cells complemented with wild-type human TDP1, 
Tdp1 − / −  hTDP1 (Fig. 3h). Importantly, Tdp1 − / −  hTDP1 − K111R cells 
accumulated ~3-fold more breaks compared with Tdp1 − / −  hTDP1  
cells (P = 0.015; t-test). Consistent with the kinetics of SSB repair, 
subsequent incubation in CPT-free medium for short periods 
resulted in a decline in the level of SSBs observed in all three 
cell lines. Notably, levels of SSBs remained at a higher level in 
Tdp1 − / −  hTDP1 − K111R compared with Tdp1 − / −  hTDP1 cells. To exam-
ine whether unrepaired SSBs in Tdp1 − / −  hTDP1 − K111R impacted on 
cellular survival, we compared the three cell types for their ability to 
form macroscopic colonies following exposure to CPT. Tdp1 − / −  V  
cells were very sensitive to CPT and, as expected, complemen-
tation with hTDP1 led to marked protection, whereas comple-
mentation with hTDP1K111R led to partial protection (Fig. 3i,j). 
Furthermore, complementation of Tdp1 − / −  quiescent cortical 
neural cells with human TDP1 or TDP1K111R revealed a role for 
K111 to maintain cell viability following CPT (Fig. 3k). Taken 
together, we conclude that mutating the acceptor lysine K111 to a 
non-SUMOylatable arginine results in defects in repairing SSBs.
K111R does not alter TDP1 structure or catalytic activity. Why 
does a TDP1 SUMOylation-defective mutant display attenuated 
rates of SSB repair? Although unlikely for missense point muta-
tions, we tested the possibility that the K111R mutation might 
lead to a gross distortion of TDP1 structure. We subjected recom-
binant TDP1 and TDP1K111R produced in Escherichia coli to 
thermal denaturation experiments, a widely used technique to 
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Figure 2 | TDP1 is SUMOylated at Lysine 111. (a,b) BLAsT analysis identifies TDP1 orthologues in plants, fungi and animals with an extended amino 
terminus in vertebrates ‘dotted boxes’. sequence analysis of this domain identifies two putative sumoylation sites. Alignment of sequences from human 
(Homo sapiens; NP_001008744), cattle (Bos taurus; NP_001180084; XP_874680), monkey (Pongo abelii; XP_002825063), chicken (Gallus gallus; XP_421313), 
frog (Xenopus tropicalis; NP_001039242), fish (Danio rerio; XP_700174) using uniProt software identifies K111 (highlighted in grey) as a conserved residue. 
(c) Purified human TDP1 encompassing the first 150 amino acids TDP11 − 150 ‘WT’ and equivalent versions, in which lysine 111, 139 or both were mutated to 
arginine ‘K111R, K139R and K111R; K139R, respectively’ were subjected to sumoylation reactions containing 50 nm sAE1/sAE2, 500 nm uBC9 and 5 mm 
ATP in the presence of 30 µm WT sumo1 (lanes 1–4) or mutant sumo1 (lanes 5 and 6). Reaction products were fractionated by sDs–PAGE and analysed 
by immunoblotting with anti-TDP1 (ab4166; Abcam) or anti-sumo1 (Activemotif) antibodies. (d) Purified full-length human TDP1 ‘WT’ or TDP1K111R 
‘K111R’ was subjected to sumoylation reactions and analysed by immunoblotting. (e) HEK293 cells were transfected with ‘ + ’ or without ‘ − ’ GFP–sumo1 
and with wild-type myc–TDP1 or a version harbouring substitution of K111 ‘n1’, K139 ‘n2’, K111 and K139 ‘n1/2’, K231, K417 and K527 ‘C’ or K111, K139, 
K231, K417 and K527 ‘nC’ to arginine. Total cell extract (~4×106 cells) was subjected to immunoprecipitation using anti-myc monoclonal antibodies 
(9B11; Cell signaling) and immunoprecipitates were fractionated by sDs–PAGE and analysed by immunoblotting. molecular weight size markers (kDa) are 
depicted. mT, mutant; WT, wild type.
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examine structural changes of proteins24. The K111R mutation had 
no detectable impact on the thermal stability or unfolding profile 
of TDP1, as determined by comparing the denaturation curves 
and their corresponding melting temperatures (Fig. 4a). We also 
compared the circular dichroism absorption spectrum of TDP1 
and TDP1K111R (Fig. 4b–d). The two proteins gave spectral shapes 
with negative bands at ~210 and 220 nm, and positive bands at 
~195 nm. Analyses of secondary structure by the variable selection 
algorithm (CDSSTR), which provides superior fits for globular pro-
teins25–28, revealed no significant difference in α-helical or β-sheet 
content (P > 0.5; t-test), suggesting no apparent change in structure 
(Supplementary Table S1). This was also supported by using the 
CONTIN and K2D algorithms (Supplementary Tables S2 and S3). 
To further examine the impact on protein folding and catalytic activity, 
we incubated purified recombinant TDP1 or TDP1K111R with oli-
gonucleotide duplexes harbouring 3′-phosphotyrosine that mimic 
Top1-linked breaks and quantified the 3′-phosphate products. The 
reactions showed a comparable concentration-dependent conver-
sion of 3′-phosphotyrosine to 3′-phosphate, suggesting no impact of 
the K111R mutation on catalytic activity (Fig. 4e,f). Taken together, 
we conclude that mutation of the SUMOylation site of TDP1 to a 
non-SUMOylatable version results in delayed rate of SSB repair 
without a measurable impact on structure or catalytic activity.
SUMOylation of  TDP1 does not alter enzymatic activity. Next, 
we considered the possibility that SUMOylation may alter protein 
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Figure 3 | The SUMOylation-deficient mutant TDP K111R displays attenuated rate of SSB repair. (a) HEK293 cells were transfected with GFP–sumo1 
and empty vector ‘vector’, or vectors encoding myc–TDP1 ‘TDP1’ or myc–TDP1K111R ‘TDP1 K111R’ using conditions that produce  > 90% transfection 
efficiency. Cells were incubated with Dmso ‘mock’ or 50 µm camptothecin ‘CPT’ and DnA breaks quantified by alkaline comet assays (ACA). mean 
tail moments were quantified for 50 cells per sample per experiment, and data are the average of n = 3 biological replicates ± s.e.m. (b) Lysate from cells 
used in a was analysed by immunoblotting. (c) A representative scatter plot from one experiment showing comet tail moments of 50 individual cells per 
sample. (d) HEK293 cells transfected with the indicated TDP1 constructs and an empty GFP ‘ − sumo1’ or GFP1–sumo1 ‘ + sumo1’ vector were analysed 
by ACA. (e) Lysate from cells used in d were analysed by immunoblotting. (f,g) HEK293 were exposed to ionizing radiation (20 Gy) and DnA breaks 
quantified immediately following irradiation (f) or after subsequent incubation for the indicated repair periods by ACA (g). The fraction of DnA breaks 
remaining was calculated from n = 3 biological replicates and depicted as % damage remaining ± s.e.m. (h) Tdp1 − / −  mEFs infected with virus particles 
encoding vector alone, human TDP1 or human TDP1 K111R were subjected to 20 µm CPT followed by subsequent incubation in CPT-free media for  
60 min, and DnA breaks were quantified by ACA. (i) Tdp1 − / −  mEFs were mock-treated or treated with the indicated doses of CPT, and the number of 
surviving colonies was calculated from n = 4 biological replicates ± s.e.m. (j) Tdp1 − / −  mEFs lysate from experiments in i was analysed by immunoblotting. 
(k) Tdp1 − / −  primary cortical neural cells electroporated with empty GFP vector or vectors expressing human GFP–TDP1 or GFP–TDP1K111R were exposed to 
30 µm CPT (4× 30 min pulse every 3 h) and viability of GFP-positive cells quantified using propidium iodide exclusion. Error bars, range of error for  
n = 2 biological replicates. statistical analyses were conducted using student’s t-test, and asterisks denote P < 0.05 difference between TDP1 (yellow)  
and TDP1 K111R (blue). Where not visible, error bars are smaller than the symbols.
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function by introducing structural changes that result in changes 
in enzymatic activity29,30. To test this possibility, we subjected 
human recombinant TDP1 or TDP1K111R to SUMOylation reac-
tions in the presence of wild-type SUMO1 or mutant SUMO1 (Fig. 
4g) and incubated reaction products with the synthetic Top1 sub-
strates (Fig. 4h–j). We also compared the effect of SUMOylation on 
TDP1 produced in mammalian cells (Fig. 5a,c,e,f). Furthermore, we 
subjected purified human SUMOylated TDP1 to SENP1 treatment 
and compared the activity of the resulting products to that of mock-
treated fractions (Fig. 5b,d,g,h). Incubation of Myc–TDP1 with 
Top1-substrate mimics resulted in a dose-dependent conversion of 
3′-phosphotyrosine to 3′-phosphate, indicating that TDP1 catalytic 
activity was not affected by Myc, His or GFP tags. Quantification 
of reaction products at different concentrations or at different time 
points revealed no marked impact of SUMOylation on TDP1 activ-
ity (Fig. 5e–h). We conclude from these experiments that SUMO1 
conjugation to TDP1 does not affect its enzymatic activity. We also 
excluded the possibility that TDP1 SUMOylation might modu-
late interaction with DNA ligase IIIα (Lig3α), a known binding 
partner and a component of the SSB repair machinery (Fig. 6a,b). 
Using western blotting, we could not detect a measurable increase 
of TDP1 SUMOylation after exposure to exogenous DNA damage 
(Supplementary Fig. S1). This suggests that TDP1 SUMOylation is a 
housekeeping modification that occurs, as is also the case with other 
SUMO1-modified targets such as fission yeast Top1 and human 
Kap1 (refs 31 and 32), at low steady-state levels where cycles of 
–10.0
–5.0
5.0
0.0
200 210 220 230 240 250 260
CD
 (m
de
g)
–15
–10
–5
0
5
10
TDP1 TDP1 K111R
P
PY
18
PY
32P 25
Temperature (°C)
N
or
m
al
iz
ed
  r
el
at
ive
 fl
uo
re
sc
en
ce
(fr
ac
tio
n u
nfo
lde
d)
Wavelength (nm)
TDP1
(θ210 = –7.5 ± 1.8)(θ220 = –5.6 ± 1.2)
TDP1 K111R
(θ210 = –7.7 ± 1.9)(θ220 = –5.5 ± 1.3) 
195
0
10
20
30
40
50
60
70
80
90
100
0 3 7 15 30
%
 C
on
ve
rs
io
n 
to
 3
′-p
ho
sp
ha
te
TDP1 (nM)
TDP1
TDP K111R
–
His–TDP1
His–TDP1
GST–SUMO1
WT K111R
TDP1
Anti-TDP1
–
WT SUMO1 MT SUMO1
P
PY
0
10
20
30
40
50
60
70
80
90
100
0 5.5 11 22 110
%
 C
on
ve
rs
io
n 
to
 3
′-p
ho
sp
ha
te
TDP1 (nM)
0
10
20
30
40
50
60
70
0 5.5 11 22 110
TDP1 (nM)
WT SUMO1
MT SUMO1
WT SUMO1
MT SUMO1
%
 C
on
ve
rs
io
n 
to
 3
′-p
ho
sp
ha
te
100
75
20 30 40 50 60 70
TDP1
(Tm= 54.3 ± 0.012 °C)
TDP1 K111R
(Tm= 55.5 ± 0.014 °C)
1.0
0.8
0.6
0.4
0.2
0.0
200 210 220 230 240 250 260
250
300
350
400
450
500
550
600
H
T[V
]
CD
 (m
de
g)
195 200 220 240 260
Wavelength (nm)
His–TDP1
His–TDP1
His–SUMO1
WT MT
SUMO1
Anti-TDP1
100
75
Wavelength (nm)
Figure 4 | The K111R mutation does not result in a measurable change of TDP1 structure or catalytic activity. (a) Recombinant TDP1 or TDP1K111R  
was mixed with sYPRo-orange, and melting profiles were obtained between 20 and 70 °C using a ramping rate of 0.03 °C s − 1. Data were normalized  
to a fraction of protein in its denatured state and presented as normalized relative fluorescence. melting temperatures (Tm) were determined according  
to the Boltzmann model55. Error bars represent s.d. from n = 3 independent replicates. (b,c) Recombinant TDP1 or TDP1K111R was placed in a 0.2-mm 
quartz cuvette and the circular dichroism spectrum determined using a JAsCo J-715 spectropolarimeter. scans were performed from 260 to 195 nm, buffer 
baselines were subtracted, and data recorded with a high-tension voltage ‘HT [V]’  < 550 V. Data represent the average of n = 4 independent replicates ± s.
e.m. (d) subtraction of the TDP1 K111R spectra from that of TDP1 shows no gross structural difference. (e) Decreasing concentrations (30, 15, 7 and 3 nm) 
of purified recombinant TDP1 or TDP1K111R was incubated with a 32P-radiolabelled duplex-nicked substrate (50 nm) harbouring a 3′-phosphotyrosine ‘PY’ 
at the nick (inset). Repair products were analysed by denaturing PAGE and phosphorimaging. Positions of the 32P-radiolabelled substrate ‘PY’ and product 
‘P’ are indicated by arrows. (f) Reaction products ‘P’ were quantified relative to total labelled substrate ‘P + PY’ and percentage conversion to 3′-P from 
experiments conducted in e was quantified. (g) Recombinant TDP1 or TDP1K111R was subjected to in vitro sumoylation reactions in the presence of wild-
type sumo1 ‘WT’ or mutant sumo1 ‘mT’ and analysed by immunoblotting. (h–j) serial dilutions of sumoylation reactions were subsequently mixed 
with Top1–DsBs (h,i) or Top1–ssBs (j) and analysed by denaturing PAGE and phosphorimaging. Reaction products were quantified relative to total labelled 
substrate and percentage conversion to 3′-P was quantified. Error bars, s.e.m. of n = 3 independent experiments.
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conjugation and deconjugation are associated with endogenous lev-
els of DNA breaks. Furthermore, SUMOylation did not alter TDP1 
nucleolar exclusion after DNA damage, as determined by live and 
fixed cell fluorescence microscopy (Fig. 6c–e).
SUMOylation aids accumulation of TDP1 at sites of DNA damage. 
We next considered the possibility that TDP1 SUMOylation 
might affect its local concentration at sites of DNA damage. This 
would be an appealing mechanism to increase substrate spectrum, 
as in vitro data suggest a requirement for a high concentration of 
TDP1 to process SSBs16,23. The difference in unrepaired SSBs that 
accumulate in TDP1K111R compared with TDP1-expressing cells 
could be attributed to differences in the local concentration of 
TDP1 at sites of DNA damage (Supplementary Fig. S2). To exam-
ine whether TDP1 SUMOylation fulfils this function, we compared 
the accumulation of GFP–TDP1 to that of GFP–TDP1K111R at sites 
of ultraviolet A laser-induced DNA damage in mammalian cells. 
Laser damage induces a mixture of nicks, gaps, SSBs and DSBs, all 
of which have been shown to trap Top1, resulting in Top1–DNA 
breaks33–35. In addition, a subset of these breaks may be direct sub-
strates for TDP1 (refs 7,12 and 36). While GFP–TDP1 accumulated 
rapidly at sites of laser damage reaching a maximum level within 
5 s, accumulation of GFP–TDP1K111R was slower and less exten-
sive (Fig. 7a–c). Interestingly, accumulation of GFP–TDP1K111R 
continued to increase over the entire time course of the experi-
ment, perhaps reflecting the need to continue protein accumula-
tion to achieve levels similar to that seen with GFP–TDP1. 90 s after 
DNA damage, the local enrichment of GFP–TDP1 at laser stripes 
was ~150% compared with ~125% for GFP–TDP1K111R (Fig. 7a). 
This difference was not due to differences in TDP1 expression, 
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Extracts were fractionated by sDs–PAGE and 1/10 serial dilutions analysed by immunoblotting using anti-myc antibodies. (b) Lysates from HEK293  
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myc-immunoprecipitation. The immunoprecipitate was then incubated with buffer alone ‘ − ’ or buffer containing 1 µg sEnP1 ‘ + ’. Purified  
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from n = 2 biological replicates.
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as the global expression was similar by western blotting (Fig. 7a, 
inset) and, more importantly, only cells that showed similar level 
of GFP–TDP1 total fluorescence were subjected to the tracking 
experiments (Fig. 7b). Notably, the K111R mutation did not ablate 
recruitment completely, suggesting that either recruitment is par-
tially SUMOylation-dependent or other SUMO sites, although not 
detected biochemically, may contribute to the remaining fraction of 
enrichment.
If it is true that TDP1 SUMOylation promotes repair by facili-
tating its accumulation at sites of DNA damage, then depletion of 
UBE2I (UBC9), the obligate SUMO-conjugating enzyme, should 
similarly reduce accumulation of TDP1 at sites of DNA damage. 
To test this, we depleted UBC9 in MRC5 cells using short hair-
pin RNA and compared the accumulation of GFP–TDP1. As 
predicted, depletion of UBC9 led to a marked reduction of the 
ability of GFP–TDP1 to accumulate at sites of laser damage 
(Fig. 7b–f). Enrichment of GFP–TDP1 in UBC9-depleted cells 
displayed similar dynamics to that of GFP–TDP1K111R, as it contin-
ued to increase during the time course of the experiment. Impor-
tantly, depletion of UBC9 did not result in further reduction in the 
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Figure 6 | The K111R mutation does not alter TDP1 subcellular localization or interaction with Lig3. (a) Yeast Y190 cells harbouring pGBKT7–TDP1 or 
pGBKT7–TDP1K111R and pACT or pACT–Lig3α constructs were plated onto selective media either containing ‘control’ or lacking ‘His’ histidine to test for the 
activation of the His3 reporter gene. Activation of the β-Gal reporter gene was determined using filter lifts from control plates. Expression levels of myc–TDP1 or 
myc–TDP1K111R (Gal4-binding domain fusion protein) and Lig3α (Gal4-activation domain fusion) were determined by immunoblotting with anti-myc (9B11; Cell 
signalling) or anti-Gal4 AD antibodies (06-283; millipore). (b) HEK293 cells (~4×106) were transfected with myc–TDP1 and GFP–sumo1, and total cell extract 
subjected to immunoprecipitation using anti-myc monoclonal antibodies (9B11; Cell signaling). Immunoprecipitates were fractionated by sDs–PAGE and analysed 
by immunoblotting using anti-myc (top) or anti-Lig3α antibodies (bottom). Input is ~5% of total cell extract used. (c) Human mRC5 cells were plated onto glass-
bottom dishes and transfected with pmCEGFP–TDP1. Cells were incubated with Dmso ‘Dmso’ or 2 µm CPT ‘CPT’ for 1 h at 37 °C. DnA was counterstained with 
Hoechst 33285, and GFP-positive cells photographed with a ×40/1.2-W objective using a Zeiss Axiovert confocal microscope. Arrowheads point at the position of 
nucleoli. (d,e) A549 cells transiently transfected with pmCEGFPP–TDP1 ‘GFP–TDP1’ or the sumoylation-deficient mutant pmCEGFPP–TDP1K111R ‘GFP–TDP1 K111R’ 
were mock treated ‘mock’ or incubated with 30 µm CPT ‘CPT’ for 30 min at 37 °C. Cells were then fixed, DnA counterstained with 4,6-diamidino-2-phenylindole, 
and analysed with a ×60/oil objective using a Deltavision microscope. A representative images depicting cells with GFP–TDP1 excluded from nucleoli ‘excluded’, 
concentrated in nucleoli ‘enriched’ or exhibited pan-nuclear distribution ‘Pan-nuclear’ are shown in d. The average number of cells with the indicated GFP–TDP1 
localization pattern was measured from a total of ~60 cells and presented as average ± s.e.m. from n = 3 biological replicates; scale bar, 10 µm.
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accumulation of GFP–TDP1K111R, indicating that the observed 
effect was due to SUMOylation. Taken together, these results 
indicate that SUMOylation of TDP1 at K111 facilitates its accumu-
lation at sites of DNA damage, thereby enhancing its DNA repair 
capacity.
Contribution to the repair of transcription-associated SSBs. 
A major source of Top1-breaks is the collision of Top1 intermediates 
with elongating RNA polymerases during transcription. Inhib-
iting RNA polymerase II by 5,6-dichlorobenzimidazole 1-b-d- 
ribofuranoside (DRB) or α-amanitin has been shown to reduce the 
extent of CPT-induced DNA SSBs4,37. We reasoned that if TDP1 
SUMOylation contributes to its recruitment to sites of transcription- 
associated SSBs, then inhibiting transcription should result in 
reduced accumulation of TDP1. Consistent with this prediction, 
pretreatment of GFP–TDP1-expressing cells with the transcription 
inhibitor DRB led to reduction in TDP1 accumulation at sites of 
laser damage (Fig. 8a,b). The reduction in recruitment was less than 
that observed for mock-treated GFP–TDPK111R, which could reflect 
a role for TDP1 SUMOylation during damage generated by DRB-
resistant RNA polymerases. Alternatively, it could be due to roles 
for TDP1 SUMOylation unrelated to transcription. Importantly, 
DRB did not affect the initial recruitment of GFP–TDP1K111R, 
suggesting a role for TDP1 SUMOylation at K111 during the repair 
of transcription-blocking lesions. However, DRB ablated the time-
dependent increase of GFP–TDP1K111R accumulation during the 
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Figure 7 | TDP1 SUMOylation promotes its accumulation at sites of DNA damage. (a) Human mRC5 cells were plated onto glass-bottom dishes 
and transfected with pmCEGFP–TDP1 ‘TDP1’ or pmCEGFP–TDP1K111R ‘TDP1 K111R’. Cells expressing similar total GFP signal were locally irradiated with 
a ultraviolet A laser, and GFP–TDP1 accumulation at the site of damage was quantified for the indicated time periods (seconds), where ‘C’ represents 
undamaged and ‘0’ the enrichment obtained immediately after damage. Data are plotted as the percentage increase in fluorescence (arbitrary units) 
at the site of ultraviolet A irradiation. Data are the average ± s.e.m. of ~60 cells measured from n = 6 biological replicates. The difference between the 
accumulation of GFP–TDP1 (yellow circles) and GFP–TDP1 K111R (blue circles) was statistically significant at all time points examined (P < 0.001, student’s 
t-test). Global expression of GFP–TDP1 was analysed by immunoblotting using anti-TDP1 antibodies, inset. (b) Average total fluorescence ± s.e.m. from 
cells analysed in a showing comparable level of expression between GFP–TDP1 and GFP–TDP1K111R. (c) Representative images of cells from experiments 
presented in a are shown before irradiation ‘control’, immediately after ‘0 s’ and at the indicated time points ‘5–40 s’. scale bar, 10 µm. (d) mRC5 cells 
were transfected with non-silencing control constructs ‘CT’ or with constructs encoding short hairpin RnA to UBC9 ‘uBC9 KD’ and stable cells were 
subsequently transfected with pmCEGFP–TDP1 ‘TDP1’ or with pmCEGFP–TDP1K111R ‘TDP1 K111R’. Cells expressing similar total GFP signal were locally 
irradiated with an ultraviolet A laser, and GFP–TDP1 accumulation at the site of DnA damage was quantified as described in a. Data are the mean ± s.e.m. 
of ~40 cells measured from n = 3 biological replicates. (e) Average total fluorescence ± s.e.m. from cells analysed in d showing no difference in expression 
levels between GFP–TDP1 and GFP–TDP1K111R. (f) Lysate from control ‘CT’ or uBC9-depleted ‘uBC9 KD’ cells were fractionated by sDs–PAGE and 
analysed by immunoblotting using anti-uBC9 (Abcam) or anti-actin antibodies.
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subsequent 90-s observation period. We reason that inhibiting 
transcription may reduce the frequency of collision of Top1 inter-
mediates with elongating RNA polymerase II, thereby reducing the 
need for recruiting more GFP–TDP1K111R. We next quantified the 
extent of transcription-associated SSBs using alkaline comet assays. 
For these experiments, we used HEK293 cells to achieve ~90% 
transfection efficiency. If the difference in repair capacity observed 
between TDP1 and TDP1K111R was, at least in part, due to a role 
for TDP1 SUMOylation in repairing transcription-associated SSBs, 
then inhibiting transcription should ablate or reduce this difference. 
While cells expressing TDP1K111R accumulated a higher level of 
SSBs compared with TDP1 expressing cells, they both decreased to a 
comparable level following incubation with DRB (Fig. 8c,d; P = 0.78; 
t-test), suggesting that TDP1 SUMOylation contributes to the repair 
of transcription-associated SSBs. Taken together, these data suggest 
that TDP1 SUMOylation at K111 participates in the overall repair 
of transcription-dependent SSBs.
Discussion
Top1-linked DNA breaks underlie the clinical utility of an important 
class of anticancer drugs, and their progressive accumulation causes 
neurodegeneration in humans1,38–40. A key factor in the repair of 
Top1-breaks is TDP1, mutation of which causes the demise of post-
mitotic tissue. Here we report that TDP1 is a substrate for SUMO 
modification, which occurs primarily at lysine 111 within the vertebrate- 
conserved N-terminal domain. SUMOylation promotes accumula-
tion of TDP1 at sites of DNA damage, thereby accelerating the rate of 
SSB repair and contributes, at least in part, to the repair of transcrip-
tion-generated SSBs, the major source of Top1-breaks in non-cycling 
cells. These observations raise the possibility of an important regula-
tory role in postmitotic tissue. Notably, ~4-fold difference in the rapid 
clearance of SSBs results in severe neurological dysfunction in murine 
model systems22 and has been linked to ataxia in humans1,41,42.
Collision of elongating RNA polymerase II with Top1 inter-
mediates results in stalling of transcription and triggers partial 
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Figure 8 | Accumulation of TDP1 at sites of DNA damage is in part transcription dependent. (a) mRC5 cells expressing GFP–TDP1 or GFP–TDP1 K111R 
were incubated with Dmso ‘-DRB’ or with 50 µm 5,6-dichlorobenzimidazole 1-b-d-ribofuranoside ‘ + DRB’ for 2 h at 37 °C. Cells expressing similar  
total GFP signal were irradiated with an ultraviolet A laser, and GFP–TDP1 accumulation at the site of damage was quantified. Data are the mean ± s.e.m.  
of ~40 cells from n = 4 biological replicates. note that the difference between the accumulation of GFP–TDP1 in the absence (yellow circles) and  
presence (yellow triangles) of DRB was statistically significant (P < 0.05, student’s t-test). (b) Average total fluorescence ± s.e.m. for cells analysed in a. 
(c) HEK293 cells were transfected with empty vector ‘vector’, myc–TDP1 ‘TDP1’ or myc–TDP1K111R ‘TDP1 K111R’ and GFP–sumo1. Cells were incubated 
with Dmso ‘mock’ or treated with 50 µm camptothecin ‘CPT’ with or without previous incubation with 50 µm DRB for 2 h. DnA strand breakage was 
quantified by alkaline comet assays and presented as mean tail moment. Data are the average ± s.e.m. from n = 3 biological replicates, where 50 cells 
per sample were blindly scored from each experiment. statistical analyses (student’s t-test) were conducted to compare the difference between TDP1 
and TDP1 K111R in the absence or presence of DRB, and the corresponding P-values are depicted. (d) Lysate from cells used for experiments in c were 
fractionated by sDs–PAGE and analysed by immunoblotting. (e) Collision of elongating RnA polymerases, such as RnA Pol II with Top1 intermediates, 
leads to stalling of the polymerase with subsequent proteasomal degradation of Top1, and possibly the stalled RnA Pol. We propose that these 
collision events recruit TDP1 to sites of polymerase stalling. TDP1 exists in equilibrium between unmodified (the majority) and a sumoylated version 
(a tiny proportion), and the balance is maintained by the opposing activities of sumo conjugation (sAE1/2, uBC9 and possibly a sumo ligase) and 
deconjugation (sEnPs). We show that TDP1 sumoylation occurs primarily at K111 and propose that sumoylated TDP1 is at least, in part, engaged  
in dealing with the transcription-blocking lesions.
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degradation of Top1 to a small peptide43. TDP1 can then access 
these structures to remove the stalled Top1 peptide from DNA ter-
mini23,44. We propose that collision with RNA polymerases is a trig-
ger to degrade Top1 and to subsequently enrich TDP1 at sites of 
DNA damage (Fig. 8e). The latter process is, at least in part, depend-
ent on SUMOylation of TDP1 at lysine 111. We propose a further, 
evolutionarily conserved, layer of regulation via a SUMO–SIM 
interaction that maintains TDP1 at sites of DNA damage. There is 
precedence for the involvement of SUMO during Top1 repair. Top1 
itself, the main source of DNA breaks that require TDP1, is also a 
substrate for SUMO conjugation45,46. In fission yeast, the SUMO 
conjugation machinery also has a role for dealing with Top1-
breaks47. The Nse2 E3 SUMO ligase functions together with the 
fission yeast structure-specific nuclease Rad16-Swi10 to facilitate 
the repair of Top1-breaks, independently of Tdp1 (refs 32 and 48). 
Notably, lysine 111 is absent in fission yeast Tdp1, highlighting an 
evolutionarily driven SUMO regulation for human TDP1.
Mutation of the SUMO acceptor lysine 111 to arginine did not 
result in an apparent impact on the core structure of TDP1, as indi-
cated by the thermal shift profiles, circular dichroism spectrograms 
and by comparing enzymatic activities of the recombinant proteins. 
While CD spectra showed no significant change in α-helical or 
β-sheet content, it pointed at a possible minor change in conforma-
tion, which is unlikely to be of biological relevance, as enzymatic 
activities was not affected. Moreover, cellular TDP1 and TDP1K111R 
interacted to the same extent with Lig3α, which is known to bind to 
that domain17,18, as measured by two independent assay methods 
(Fig. 6). Knockdown of UBC9 reduced recruitment of TDP1 to a 
level similar to that of TDP1K111R, but had no impact on TDP1K111R 
recruitment, indicating that the difference was due to SUMOyla-
tion. Furthermore, overexpression of SUMO1 facilitated repair of 
cells expressing TDP1, but not TDP1K111R, further supporting that 
the observed phenotype was due to SUMOylation.
Crystal structure, cell-free and DNA binding studies suggest 
that high local concentrations of TDP1 are required to process 
Top1–SSBs16,49,50. However, how vertebrate cells achieve this was 
not clear5,16,51. Here we examined whether SUMOylation of TDP1 
increased its catalytic activity, using the 3′-phosphotyrosine sub-
strate to mimic Top1-linked DNA breaks. SUMOylated TDP1 pre-
pared in vitro or purified from mammalian cells exhibited similar 
catalytic activity to the unSUMOylated version. It is possible that 
SUMOylation facilitates binding of Top1 peptide to the peptide-
binding pocket of TDP1 and thus increases catalytic activity when 
using a peptide substrate instead of a phosphotyrosine substrate. 
However, we do not favour this possibility, as the peptide-binding 
pocket is distant form the SUMOylation site. Instead, our results 
show that SUMOylation promotes TDP1 accumulation at sites of 
DNA damage, ensuring sufficiently rapid and proficient repair of 
SSBs (Figs 7 and 8). SUMOylation has been previously implicated 
in concentrating enzymatic activities and triggering the forma-
tion of nuclear assemblies, such as PML bodies52,53; however, it 
has not been linked to repair of SSBs, a highly abundant form of 
endogenous DNA damage and a major threat to genome integrity. 
Notably, we observed that persistent overexpression of TDP1, but 
not the SUMOylation-defective mutant, was poorly tolerated in 
mammalian cells. This is likely due to the efficient accumulation 
of TDP1 at damaged sites with subsequent generation of excessive 
3′-phosphate termini that require further processing by limiting 
downstream factors such as PNK54. Thus, SUMOylation appears 
to target specifically a subset of TDP1 to promote sufficiently rapid 
turnover of endogenous Top1–SSBs. It is not known at what level 
Top1-breaks arise in cells. However, the fact that they do arise in 
the absence of exogenous DNA damage is suggested by the pro-
gressive degeneration of the cerebellum of patients with defective 
TDP1 and by experiments in fission yeast where depletion of 
Tdp1 and parallel pathways led to the generation of Top1-breaks1,32. 
Thus, devising efficient mechanisms to deal with endogenous 
Top1-breaks is critical for the maintenance of genetic integrity, 
particularly in postmitotic tissue.
In summary, we report here that human TDP1 is SUMOylated at 
lysine 111 and that SUMOylation promotes its accumulation at sites 
of damaged DNA, thereby facilitating the repair of SSBs. These data 
identify a molecular role for SUMOylation during TDP1-mediated 
SSB repair reactions and implicates this process in protecting post-
mitotic tissue from genotoxic stress.
Methods
Yeast two-hybrid screen and analyses. Sacharomyces cerevisiae Y190 cells 
(Clontech) were transformed with pGBKT7–TDP1S81E, and transformants were 
plated onto minimal media plates (glucose and yeast nitrogen base without amino 
acids) additionally containing adenine, histidine and leucine. Pooled populations 
of transformants were streaked and single clones picked to ensure good expression 
of the fusion proteins. Y190 cells expressing pGBKT–TDP1S81E were transformed 
with 16 µg of pACT human cDNA library and transformants plated onto minimal 
media supplemented with adenine and 50 mM 3-amino-1,2,4-triazole (3AT), but 
lacking leucine, tryptophan and histidine (His-). The activation of the His reporter 
gene was indicated by growth on His- plates after 4–7 days at 30 °C. A total number 
of 5×106 clones were screened, as estimated from the transformation efficiency on 
minimal media plates with adenine and histidine. Healthy-looking colonies were 
isolated, rescreened for growth on His- plates. Potential clones were tested for  
the activation of the β-Gal reporter by qualitative X-Gal (5-bromo-4-chloro- 
3-indolyl-β-d-galacto-pyranoside) assays on colony filter lifts from control plates. 
Following confirmation of positive clones, the corresponding pACT constructs 
were isolated and subjected to sequencing. We identified 14 independent clones 
encoding full-length human UBE2I according to the published DNA sequence 
(NM_003345). Antibodies used for the detection of fusion proteins are listed in 
Supplementary Methods.
Cell-free SUMOylation assays. The generation and purification of recombinant 
proteins and their quantification are detailed in Supplementary Methods. Puri-
fied His–TDP1 or His–TDP1 mutants (430 nM) were incubated with purified 
SAE1/SAE2 (50 nM), UBC9 (500 nM), SUMO1, SUMO2 or SUMO3 (30 µM) in 
50 mM Tris–HCl, pH 8.0; 50 mM NaCl, 5 mM MgCl2, 10% glycerol, 0.5 mM DTT 
and 5 mM ATP (Activemotif). Reactions were incubated at 30 °C for 3 h unless 
otherwise indicated, followed by fractionation on SDS–PAGE and analyses by west-
ern blotting using anti-SUMO1, anti-SUMO2/3, anti-p53 (Activemotif, 1:3,000) or 
anti-TDP1 polyclonal antibodies (ab4166; Abcam, 1:2,000). Note that we noticed 
a nonspecific binding of the anti-SUMO1 antibodies (Activemotif) to unmodified 
SUMO1 targets. To confirm that the modification is in fact for SUMO1, we also 
used anti-SUMO1 monoclonal antibodies from Santa Cruz (clone 0–11; SC-5308, 
1:2,000). While both antibodies recognized the same SUMOylated species, the  
latter did not pick up the unmodified protein.
Circular dichroism spectroscopy. Recombinant proteins were dialysed in 30 mM 
sodium phosphate buffer, pH 7.4, and filtered immediately before the spectrum  
was obtained through 0.2-micron filters (Millipore). The concentration of  
recombinant proteins was accurately determined immediately before, during  
and after the CD scans, to ensure accurate secondary structure estimations. 
Samples were normalized to the lowest concentration (0.6 mg ml − 1), placed in 
a 0.2-mm quartz cuvette (Starna, Essex, UK) and measurements taken using a 
JASCO J-715 spectropolarimeter (JASCO). The CD spectrum of the buffer alone 
was subtracted from that of the sample, and time constant was set to 4 s with a  
scan rate at 50 nm min − 1. The bandwidth was 1 nm and the sensitivity set to 
standard. Scans were performed from 260 to 190 nm with a 0.1-nm data pitch and 
continuous scan mode. A Peltier device was used to maintain a temperature at 
10 °C. The buffer baselines were subtracted and data represent the average of four 
independent experiments ± s.e.m.
Immunoprecipitation. The generation and maintenance of mammalian cells are  
provided in Supplementary Methods. HEK293 (~1.5×106) cells were transfected 
using standard calcium phosphate precipitation, and 2 days later, cells were lysed in 
200 µl lysis buffer (20 mM HEPES pH7.4, 0.5% NP40, 40 mM NaCl, 2 mM MgCl2,  
1× protease inhibitor cocktail (Roche) 1× phosphatase inhibitor cocktail (Roche), 
20 mM N-ethyl maleimide, 25 U ml − 1 benzonase (Merck)). Lysates were incubated 
for 30 min on ice, cleared by centrifugation at 13,000 r.p.m. for 10 min, and NaCl 
concentration adjusted to either 150 mM for coimmunoprecipitation to examine 
protein–protein interaction or 300 mM to detect in vivo SUMOylation. Anti-Myc 
antibodies (9B11; Cell Signaling) were added to the lysate at 1 µl per 200 µl lysate 
volume and the mixture was rotated at 4 °C for 1 h. Following centrifugation at 
13,000 r.p.m. for 10 min, supernatant was then added to protein-G sepharose  
beads (Sigma), followed by rolling at 4 °C for 1 h. Beads were washed three times 
with wash buffer (20 mM HEPES, pH 7.4, 150 mM or 300 mM NaCl) and then 
resuspended in SDS loading buffer for analyses by immunoblotting.
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Purification of SUMOylated TDP1 from human cells. Approximately 1×107 
HEK293 cells were transfected with plasmids encoding GFP–His–SUMO1 and 
Myc–TDP1 and lysed, as described above, using 2× protease inhibitors and 30 mM 
imidazole in both the lysis and wash buffer. Following washing, SUMOylated pro-
teins were eluted from the beads using three consecutive elutions with lysis buffer 
containing 250 mM imidazole. Elution fractions were pooled and SUMOylated 
TDP1 was purified using Myc-immunoprecipitation, as described above. Beads 
enriched with SUMOylated TDP1 were finally suspended in an equal volume of 
wash buffer. Where indicated, 80 µl bead suspension enriched with purified Myc–
TDP1–SUMO1 was resuspended in 150 mM NaCl, 50 mM Tris, pH 7.5, 0.5 mM 
DTT. A volume of 40 µl bead suspension was then mock-treated or incubated with 
0.2–1 µg of human sentrin/SUMO-specific protease-1 (SENP1; Enzo Life Sciences) 
for 20 min at 37 °C. Following three consecutive washes with 150 mM NaCl, 50 mM 
Tris, pH 7.5, beads were subjected to in vitro activity assays or analysed by im-
munoblotting with anti-TDP1 or anti-Myc antibodies. Quantification of purified 
Myc–TDP1 and Myc–TDP1–SUMO1–His–GFP was conducted by comparing 
with known concentrations of recombinant His–TDP1 by western blotting. The 
latter was determined by Bradford assays, and by comparing with Coomassie-
stained BSA standards. We estimate 2 ng µl − 1 bead suspension of purified human 
Myc–TDP1 or Myc–TDP1–SUMO1–His–GFP.
Cell-free DNA repair assays. Purified recombinant proteins were subjected  
to in vitro SUMOylation reactions and the appropriate dilutions were mixed with 
50 nM 32P-labelled oligonucleotide duplexes (see Supplementary Methods for  
DNA sequence) in 8 µl total volume in 25 mM HEPES, pH 8.0, 130 mM KCl  
and 1 mM DTT. Purified SUMOylated TDP1 from mammalian cells was  
quantified as described above and serial dilutions of beads were mixed with  
50 nM 32P-labelled substrates. Reactions were incubated for 1 h at 37 °C,  
terminated by formamide loading buffer, fractionated by denaturing PAGE,  
and analysed by phosphorimaging.
Cellular SSB repair assays. HEK293 cells or Tdp1 − / −  MEFs containing empty 
vector or vectors expressing wild-type TDP1, TDP1K111R or GFP–SUMO1 were 
subjected to 20 µM CPT (MEFs) or 50 µM CPT (HEKs) for 30 min at 37 °C, or 
exposed to 20 Gy IR (caesium 137, Cammael 1000) on ice. Where indicated, cells 
were subsequently incubated in drug-free media for the indicated repair periods. 
DNA strand breakage was quantified by alkaline comet assays as described in  
Supplementary Methods.
Clonogenic survival and viability assays. Following confirmation of expression 
by anti-TDP1 western blotting, Tdp1 − / −  MEFs complemented with empty vector 
or with vectors expressing wild-type TDP1 or TDP1K111R were plated in duplicate 
into 10-cm dishes (~2,000 cells; untreated, 6,000 cells; CPT doses 2.5 and 5 µM, 
and ~10,000 cells; CPT doses 7.5 and 10 µM) and incubated at 37 °C for at least 
8 h. Cells were then mock-treated or treated with the indicated doses of CPT for 
1 h at 37 °C. Cells were washed with PBS (3×) and then incubated for 7–10 days in 
drug-free medium to form macroscopic colonies. Colonies were fixed using 90% 
ethanol and stained with 1% methylene blue. Survival was calculated by dividing 
the average number of colonies on treated plates by the average number of colonies 
on untreated plates. Cortical neural cells were grown to confluency at 20% oxygen 
to elevate the oxidative load and then deprived from growth factors for 3 days, 
followed by electroporation with GFP–TDP1 or GFP–TDP1K111R using Neon 
transfection system, according the manufacturer’s instructions (Invitrogen). Cells 
maintained at high oxygen were exposed to fractionated pulses of 30 µM CPT  
(4× 30 min pulse every 3 h), and viability of GFP-positive cells was quantified  
from blindly coded slides using propidium iodide (Sigma) exclusion.
Laser microirradiation. Exponentially growing human MRC5 cells were plated 
onto 35-mm glass-bottom dishes (MatTek) and transfected with pMCEGFP–TDP1 
or pMCEGFP–TDP1K111R using GeneJuice (Novagen), according to the manufac-
turer’s protocol. Twenty-four hours following transfection, cells were incubated 
with 10 µg ml − 1 Hoechst 33285 (Sigma) for 1 h at 37 °C before irradiation. Where 
indicated, cells were additionally incubated with DMSO or 50 µM DRB for 2 h 
before irradiation. Cells expressing similar total GFP signal were irradiated with a 
351-nm ultraviolet A (4.36 J m − 2) laser channelled through a ×40/1.2-W objective 
using a Zeiss ConfoCor 2/LSM510 combi meta point scanning confocal micro-
scope (Zeiss). Ultraviolet A was focused to an area of approximately 12 µm×0.1 µm, 
and images were captured at 5-s intervals following laser damage and quantified  
by ImageJ and LSM 520 Meta software. 
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